Aberdeen Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Aberdeen Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.5K	Buy	+65	New	+$44.2K	0.02%	242
2024 Q4	–	Sell	-280	Closed	-$294K	–	169
2024 Q3	$294K	Sell	280 -10	-3%	-$11.1K	0.19%	122
2024 Q2	$305K	Sell	290 -10	-3%	-$9.69K	0.21%	117
2024 Q1	$289K	Hold	300	–	–	0.17%	125
2023 Q4	$263K	Hold	300	–	–	0.19%	125
2023 Q3	$247K	Hold	300	–	–	0.19%	125
2023 Q2	$216K	Hold	300	–	–	0.16%	137
2023 Q1	$247K	Sell	300 -50	-14%	-$37.7K	0.18%	129
2022 Q4	$253K	Hold	350	–	–	0.19%	131
2022 Q3	$241K	Hold	350	–	–	0.21%	121
2022 Q2	$207K	Hold	350	–	–	0.16%	138
2022 Q1	$244K	Hold	350	–	–	0.17%	135
2021 Q4	$221K	Sell	350 -25	-7%	-$15.4K	0.14%	137
2021 Q3	$227K	Hold	375	–	–	0.22%	115
2021 Q2	$209K	Buy	+375	New	+$190K	0.19%	124
2020 Q3	–	Sell	-361	Closed	-$225K	–	144
2020 Q2	$225K	Sell	361 -84	-19%	-$47.7K	0.24%	112
2020 Q1	$217K	Buy	+445	New	+$184K	0.26%	105

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Aberdeen Wealth Management's REGN Position: Q2 2026 in Review

Aberdeen Wealth Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 65 shares worth $40.5K. The stake represents 0.02% of the portfolio and ranks #242 among its holdings. This is a return to the name: Aberdeen Wealth Management previously reported a position in REGN as recently as Q3 2024.

Aberdeen Wealth Management first reported a position in REGN in Q1 2020 and has held it in 17 quarters since. The position peaked at $305K in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Aberdeen Wealth Management held 65 shares of Regeneron Pharmaceuticals worth $40.5K as of Q2 2026.
Regeneron Pharmaceuticals was a new Aberdeen Wealth Management position in Q2 2026.
Regeneron Pharmaceuticals made up 0.02% of Aberdeen Wealth Management's portfolio in Q2 2026, its #242 holding.
Aberdeen Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 17 quarters since.
Aberdeen Wealth Management's Regeneron Pharmaceuticals position peaked at $305K in Q2 2024.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Aberdeen Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.